VIR's Quality Score rose 3 points on Mon, Nov 9, to 13.
Follow VIR's trial news. Pro members can get an alert when Vir Biotechnology files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 6% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and small-cap biotech stocks a median 9%.
Up 139% over the year to Nov 6 while the S&P 500 rose 11%; down 6% on Nov 5.
4 reasons, from its filings, with the timeline, for Pro members.
| Since its Dec 2021 high | Down 80% |
| Latest filing | 8-K, Nov 4 |
Vir Biotechnology filed an 8-K reporting a change of CFO
VIR closed −1.1% the next session (Oct 2).
Wed Nov 18: Jefferies 17th Annual London Global…Investor conference · date confirmed.
Expected to report Wed Feb 24, after the close
1 more date ahead: the conference, for Pro members.
$1.0B in cash
No shelf registration or at-the-market program on file in the last three years.
An officer, Vanina de Verneuil, sold 3,750 shares on Nov 3, under a planned sale. 21 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Above Averagefor quality, not price, 6 of 14 chart checks firingWhat the Quality Score means
Well above its recent run. VIR scores 13 today, against a median of 6 over its last 20 recorded sessions.
VIR is #27 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 27 |
Share count against a year before: VIR +21%, BHVN +47%, OCUL +30%, MLTX +17%.
Expected to report Wed Feb 24, after the close (in 107 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A loss of $0.57 a share, from $1.17.
“The decrease was primarily driven by a non-recurring $75.0 million milestone expense in the third quarter of 2025 due upon VIR-5525 achieving “first in human dosing” along with the recognition of cost recoveries in connection with the Company’s collaborations with Astellas and Norgine in the third quarter of 2026.”
VIR's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The increase was primarily due to higher advisory and legal fees.”
From its results filing (SEC filing · Nov 4)
Sales fell 2.1% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 3.1% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 4, 2026 | +1.3% | -6.4% | not yet |
| Aug 5, 2026 | +6.5% | -3.8% | -1.6% |
| May 6, 2026 | -4.2% | -9.9% | -9.3% |
Sales grew in three of the last seven years, to $68.6M in 2025. It made a profit in two of the eight years.
RSI 59.9, MACD above signal, above both averages. Not scored.
Officers and directors with a Form 4 in the last 12 months.
In ETFs: VIR is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
“The pharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products.”
VIR scores 13 today, which Breakaway calls Above Average. It is #27 of 281 in Biotech by Quality Score, with 6 of 14 chart checks firing. Down 6% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and small-cap biotech stocks a median 9%. Shares: 21.1% more than a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
VIR scores 13 today, which Breakaway calls Above Average (11 to 14). That is #27 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind VIR's 13.
Expected to report Wed Feb 24, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. VIR closed higher after 1 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.